Concepedia

Mark Yen

MY

Statistics

Publications

10

Citations

949

H-Index

10

Active since

1986

Affiliations

PAREXEL International (United States)(Current)

Astellas Pharma (United States)

PAREXEL International (United Kingdom)

Mark Yen is an author at PAREXEL International (United States) specializing in pharmacology, clinical pharmacology, and medicine.

ORCID

Publications per year

1986–2017

10

Publications

10

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 369 citations · Full text

, , +16

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

Marek Malík, E. Marcel van Gelderen, J H Lee et al. · Clinical Pharmacology & Therapeutics · 2012 · 148 citations

, , +17

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease

Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum et al. · Journal of Neuroinflammation · 2017 · 105 citations · Full text

, , +17

Domperidone, a new dopamine antagonist.

M C Champion, Michael N. Hartnett, Mark Yen · PubMed · 1986 · 78 citations

, , +16

QT Interval Shortening With Isavuconazole:<i>In Vitro</i>and<i>In Vivo</i>Effects on Cardiac Repolarization

James J. Keirns, Amit Desai, Donna Kowalski et al. · Clinical Pharmacology & Therapeutics · 2017 · 76 citations · Full text

, , +14

1–5 of 10